spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

3rd PDA Europe Annual Meeting

PDA - The Parenteral Drug Association Europe

26-27 June 2018
Berlin Marriott Hotel

The ongoing theme of the European Annual Meeting is Global Healthcare of the Present & the Future, as it intends to continue spanning a bridge between current demands within the global healthcare industry, the amounting advanced technological and analytical opportunities and the promising prospects personalized medicine and medicinal products bring.

The meeting will also include presentations from regulatory, industry and technology representatives from around the world.

A comprehensive exhibition including a Poster Session to catch up on the latest developments will give you the opportunity to network and interact with speakers and fellow attendees.

As is customary for PDA, the event will be accompanied by Interest Group Meetings, a thorough Education Program, and a diverse Exhibition Floor, offering plenty of food for thought, inspiration and networking opportunity.

phone +49 (0) 30 43 65 50 80
email info-europe@pda.org
web goo.gl/RxDdpR
email Am Borsigturm 60, 13507 Berlin
 
Print this page
Send to a friend
   
spacer
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

Banner of PHPL West Coast_events_95 on Samedan Banner of Nordics_Events_97 on Samedan

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>


News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement